Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NextCureNXTC -4.76%28 6-1 Month Momentum % is -52.87% as of Sep. 09, 2026. GuruFocus rates NXTC with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 1,375 Biotechnology companies, NextCure ranks worse than 89.16% on this metric.
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2026-09-09), NextCure's 6-1 Month Momentum % is -52.87%.
The industry rank for NextCure's 6-1 Month Momentum % or its related term are showing as below:
NXTC's 6-1 Month Momentum % is ranked worse than 89.16% of 1375
companies
in the Biotechnology industry
Industry Median: -11.58
vs NXTC: -52.87
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
NextCure 6-1 Month Momentum % Related Terms
NXTC vs CVM, PLRZ, BYSI: 6-1 Month Momentum % Comparison
For the Biotechnology subindustry, NextCure's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NextCure 6-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NextCure's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where NextCure's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NextCure (NXTC) has a 6-1 Month Momentum % of -52.87% as of Sep. 09, 2026. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on NextCure and its competitors. According to the industry distribution chart, NextCure ranks #1226 out of 1375 companies in the Biotechnology industry, placing it in the top 89.2%.
Is NextCure's 6-1 Month Momentum % too high?
NextCure's current 6-1 Month Momentum % is -52.87%. Based on the distribution chart, NextCure ranks #1226 out of 1375 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NextCure has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does NextCure's 6-1 Month Momentum % compare to CVM and PLRZ?
According to the Biotechnology industry distribution chart, NextCure ranks #1226 out of 1375 companies for 6-1 Month Momentum %. This places NextCure in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-1 Month Momentum % for a Biotechnology company?
A good 6-1 Month Momentum % depends on the Biotechnology industry context. However, 6-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-1 Month Momentum % mean?
A high 6-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 6-1 Month Momentum measures the total return of the stock from 6-month ago to 1-month ago. View historical data on NextCure and its competitors. NextCure's current 6-1 Month Momentum % is -52.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCure stock overvalued right now?
NextCure (NXTC) has a current 6-1 Month Momentum % of -52.87%. The current 6-1 Month Momentum % is -52.87%. NextCure's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-1 Month Momentum % calculated?
6-1 Month Momentum % is calculated from a company's financial statements. For NextCure (NXTC), the current 6-1 Month Momentum % is -52.87% as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
28GF Score
Get the complete analysis for NXTC
6-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NXTC has been successfully added to your 
